Schizophrenia and bipolar disorder: The road from similarities and clinical heterogeneity to neurobiological types

Clinica Chimica Acta

Volumn 449, Issue , 2015, Pages 49-59

  Dacquino, Claudia ^a,b   De Rossi, Pietro ^a,c   Spalletta, Gianfranco ^a,d  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; Bipolar disorder; Diagnosis; Diagnostic subtypes; Schizophrenia

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

ARTICLE; BIOMETRY; BIPOLAR DISORDER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; EMOTION; GENETIC HETEROGENEITY; GENETIC RISK; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROIMAGING; PHENOTYPE; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPTOMATOLOGY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PSYCHOLOGY;

BIOMARKERS; BIPOLAR DISORDER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84940438830     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.02.029     Document Type: Article

References (187)

1. Kraepelin E. Manic depressive insanity and paranoia 1921, ES Livingstone, Edinburgh.
2. Bramon E., Sham P.C. The common genetic liability between schizophrenia and bipolar disorder: a review. Curr Psychiatry Rep 2001, 3:332-337.
3. Murray R.M., Sham P., Van Os J., Zanelli J., Cannon M., McDonald C. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res 2004, 71:405-416.
4. Andreasen N.C., Arndt S., Alliger R., Miller D., Flaum M. Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch Gen Psychiatry 1995, 52:341-351.
5. Bleuler E. Dementia praecox or the group of schizophrenias 1950, International Universities Press.
6. Bearden C.E., Hoffman K.M., Cannon T.D. The neuropsychology and neuroanatomy of bipolar affective disorder: a critical review. Bipolar Disord 2001, 3:106-150.
7. Purcell S.M., Wray N.R., Stone J.L., et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-752.
8. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001, 58:165-171.
9. Strauss J., Carpenter W., Part Bartko J., III Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 1974, 11:61-69.
10. Carpenter W.T., Strauss J.S. The prediction of outcome in schizophrenia. IV: Eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis 1991, 179:517-525.
11. Andreasen N.C., Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982, 39:789-794.
12. Buchanan R.W., Carpenter W.T. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 1994, 182:193-204.
13. Carpenter W.T., Heinrichs D.W., Wagman A.M.I. Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry 1988, 145:578-583.
14. Strauss G.P., Jetha S.S., Ross S.a, Duke L.a, Allen D.N. Impaired facial affect labeling and discrimination in patients with deficit syndrome schizophrenia. Schizophr Res 2010, 118:146-153.
15. Kirkpatrick B., Buchanan R.W. The neural basis of the deficit syndrome of schizophrenia. J Nerv Ment Dis 1990, 178:545-555.
16. Strauss G.P., Allen D.N., Duke L.A., Ross S.A., Schwartz J. Automatic affective processing impairments in patients with deficit syndrome schizophrenia. Schizophr Res 2008, 102:76-87.
17. Kirkpatrick B., Amador X.F., Yale S.A., Bustillo J.R., Buchanan R.W., Tohen M. The deficit syndrome in the DMS-IV Field Trial: Part II. Depressive episodes and persecutory beliefs. Schizophr Res 1996, 20:79-90.
18. Fenton W.S., McGlashan T.H. Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 1992, 49:179-184.
19. Fenton W.S., McGlashan T.H. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 1994, 151:351-356.
20. Galderisi S., Quarantelli M., Volpe U., et al. Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr Bull 2008, 34:393-401.
21. Spalletta G., De Rossi P., Piras F., et al. Brain white matter microstructure in deficit and non-deficit subtypes of schizophrenia. Psychiatry Res Neuroimaging 2015, [Epub ahead of print]. 10.1016/j.pscychresns.2014.12.006.
22. Tamminga C.A., Thaker G.K., Buchanan R., et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992, 49:522-530.
23. Heckers S., Goff D., Schacter D.L., et al. Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia. Arch Gen Psychiatry 1999, 56:1117-1123.
24. Gonul A.S., Kula M., Eşel E., Tutuş A., Sofuoglu S. A Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Res Neuroimaging 2003, 123:99-205.
25. Kanahara N., Sekine Y., Haraguchi T., et al. Orbitofrontal cortex abnormality and deficit schizophrenia. Schizophr Res 2013, 143:246-252.
26. Vaiva G., Cottencin O., Llorca P.M., et al. Regional cerebral blood flow in deficit/nondeficit types of schizophrenia according to SDS criteria. Prog Neuro-Psychopharmacol Biol Psychiatry 2002, 26:481-485.
27. Delamillieure P., Fernandez J., Constans J.M., et al. Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report. Am J Psychiatry 2000, 157:641-643.
28. Buchanan R.W., Breier A., Kirkpatrick B., et al. Structural abnormalities in deficit and nondeficit schizophrenia. Am J Psychiatry 1993, 150:59-65.
29. Volpe U., Mucci A., Quarantelli M., Galderisi S., Maj M. Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 2012, 37:264-269.
30. Arango C., McMahon R.P., Lefkowitz D.M., Pearlson G., Kirkpatrick B., Buchanan R.W. Patterns of cranial, brain and sulcal CSF volumes in male and female deficit and nondeficit patients with schizophrenia. Psychiatry Res Neuroimaging 2008, 162:91-100.
31. Fischer B.A., Keller W.R., Arango C., et al. Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res 2012, 136:51-54.
32. Voineskos A.N., Foussias G., Lerch J., et al. Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA Psychiatry 2013, 70:472-480.
33. Rowland L.M., Spieker E.A., Francis A., Barker P.B., Carpenter W.T., Buchanan R.W. White matter alterations in deficit schizophrenia. Neuropsychopharmacology 2009, 34:1514-1522.
34. Kitis O., Ozalay O., Zengin E.B., et al. Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia. Psychiatry Clin Neurosci 2012, 66:34-43.
35. Ribeyre J., Lesieur P., Varoquaux O., Dollfus S., Pays M., Petit M. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia. Biol Psychiatry 1994, 36:230-236.
36. Thibaut F., Ribeyre J.M., Dourmap N., Ménard J.F., Dollfus S., Petit M. Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. Biol Psychiatry 1998, 43:24-30.
37. Spalletta G., Piras F., Alex Rubino I., Caltagirone C., Fagioli S. Fronto-thalamic volumetry markers of somatic delusions and hallucinations in schizophrenia. Psychiatry Res 2013, 212:54-64.
38. Rüsch N., Spoletini I., Wilke M., et al. Prefrontal-thalamic-cerebellar gray matter networks and executive functioning in schizophrenia. Schizophr Res 2007, 93:79-89.
39. Portas C.M., Goldstein J.M., Shenton M.E., et al. Volumetric evaluation of the thalamus in schizophrenic male patients using magnetic resonance imaging. Biol Psychiatry 1998, 43:649-659.
40. Heaton R., Chelune G., Talley J., Kay G., Curtiss G. Wisconsin card sorting test manual revised and expanded 1993, Psychological Assessment Resources, Lutz, FL.
41. Obermeier C., Dolk T., Gunter T.C. The benefit of gestures during communication: Evidence from hearing and hearing-impaired individuals. Cortex 2012, 48:857-870.
42. Troisi A., Spalletta G., Pasini A. Non-verbal behaviour deficits in schizophrenia: an ethological study of drug-free patients. Acta Psychiatr Scand 1998, 97:109-115.
43. Toomey R., Schuldberg D., Corrigan P., Green M.F. Nonverbal social perception and symptomatology in schizophrenia. Schizophr Res 2002, 53:83-91.
44. Bucci S., Startup M., Wynn P., Baker A., Lewin T.J. Referential delusions of communication and interpretations of gestures. Psychiatry Res 2008, 158:27-34.
45. Bellack A.S., Morrison R.L., Wixted J.T., Mueser K.T. An analysis of social competence in schizophrenia. Br J Psychiatry 1990, 156:809-818.
46. Dickinson D., Bellack A.S., Gold J.M. Social/communication skills, cognition, and vocational functioning in schizophrenia. Schizophr Bull 2007, 33:1213-1220.
47. Park S., Matthews N., Gibson C. Imitation, simulation, and schizophrenia. Schizophr Bull 2008, 34:698-707.
48. Catani M., Ffytche D.H. The rises and falls of disconnection syndromes. Brain 2005, 128:2224-2239.
49. Goldenberg G. Apraxia and the parietal lobes. Neuropsychologia 2009, 47:1449-1459.
50. Walther S., Vanbellingen T., Müri R., Strik W., Bohlhalter S. Impaired pantomime in schizophrenia: association with frontal lobe function. Cortex 2013, 49:520-527.
51. Dubois B., Slachevsky A., Litvan I., Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000, 55:1621-1626.
52. Roy-Byrne P., Post R.M., Uhde T.W., Porcu T., Davis D. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl 1985, 317:1-34.
53. Akiskal H.S., Bourgeois M.L., Angst J., Post R., Möller H., Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000, 59(Suppl. 1):s5-s30.
54. Colom F., Vieta E., Daban C., Pacchiarotti I., Sánchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 2006, 93:13-17.
55. Calabrese J.R., Vieta E., El-Mallakh R., et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry 2004, 56:957-963.
56. Vieta E., Berk M., Wang W., Colom F., Tohen M., Baldessarini R.J. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord 2009, 119:22-27.
57. Popovic D., Reinares M., Goikolea J.M., Bonnin C.M., Gonzalez-Pinto A., Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012, 22:339-346.
58. Goikolea J.M., Colom F., Martínez-Arán A., et al. Clinical and prognostic implications of seasonal pattern in bipolar disorder: a 10-year follow-up of 302 patients. Psychol Med 2007, 37:1595-1599.
59. Martinez-Aran a, Vieta E., Torrent C., et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord 2007, 9:103-113.
60. Popovic D., Torrent C., Goikolea J.M., et al. Clinical implications of predominant polarity and the polarity index in bipolar disorder: a naturalistic study. Acta Psychiatr Scand 2014, 129:366-374.
61. Maj M., Magliano L., Pirozzi R., Marasco C., Guarneri M. Validity of rapid cycling as a course specifier for bipolar disorder. Am J Psychiatry 1994, 151:1015-1019.
62. Coryell W., Endicott J., Keller M. Rapidly cycling affective disorder. Demographics, diagnosis, family history, and course. Arch Gen Psychiatry 1992, 49:126-131.
63. Kukopulos A., Reginaldi D., Laddomada P., Floris G., Serra G., Tondo L. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatr Neuropsychopharmakol 1980, 13:156-167.
64. Wehr T.A., Sack D.A., Rosenthal N.E., Cowdry R.W. Rapid cycling affective disorder: Contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988, 145:179-184.
65. Bauer M.S., Calabrese J., Dunner D.L., et al. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry 1994, 151:506-515.
66. Kilzieh N., Akiskal H.S. Rapid-cycling bipolar disorder. An overview of research and clinical experience. Psychiatr Clin North Am 1999, 22:585-607.
67. McGorry P.D., Purcell R., Hickie I.B., Yung A.R., Pantelis C., Jackson H.J. Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust 2007, 187(7 Suppl.):s40-s42.
68. McGorry P.D., Hickie I.B., Yung A.R., Pantelis C., Jackson H.J. Clinical staging of psychiatric disorders: A heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006, 40:616-622.
69. The Diagnostic and Statistical Manual of Mental Disorders: DSM 5 2013, American Psychiatric Association, Washington, DC.
70. International classification of diseases (ICD) 2012, World Health Organization.
71. Fava G.A., Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993, 87:225-230.
72. Harrison G., Hopper K., Aig T.C.R., et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001, 178:506-517.
73. Yung A.R., McGorry P.D. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996, 22:353-370.
74. Canu E., Agosta F., Filippi M. A selective review of structural connectivity abnormalities of schizophrenic patients at different stages of the disease. Schizophr Res 2014, 161:19-28.
75. Basser P.J., Pajevic S., Pierpaoli C., Duda J., Aldroubi A. In vivo fiber tractography using DT-MRI data. Magn Reson Med 2000, 44:625-632.
76. Ellison-Wright I., Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res 2009, 108:3-10.
77. Bora E., Fornito A., Radua J., et al. Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. Schizophr Res 2011, 127:46-57.
78. Karlsgodt K.H., Niendam T.A., Bearden C.E., Cannon T.D. White Matter Integrity and Prediction of Social and Role Functioning in Subjects at Ultra-High Risk for Psychosis. Biol Psychiatry 2009, 66:562-569.
79. Carletti F., Woolley J.B., Bhattacharyya S., et al. Alterations in white matter evident before the onset of psychosis. Schizophr Bull 2012, 38:1170-1179.
80. Clemm von Hohenberg C., Pasternak O., Kubicki M., et al. White Matter Microstructure in Individuals at Clinical High Risk of Psychosis: A Whole-Brain Diffusion Tensor Imaging Study. Schizophr Bull 2013, 40:895-903.
81. Witthaus H., Brüne M., Kaufmann C., et al. White matter abnormalities in subjects at ultra high-risk for schizophrenia and first-episode schizophrenic patients. Schizophr Res 2008, 102:141-149.
82. Bloemen O.J.N., de Koning M.B., Schmitz N., et al. White-matter markers for psychosis in a prospective ultra-high-risk cohort. Psychol Med 2010, 40:1297-1304.
83. Clark K.A., Nuechterlein K.H., Asarnow R.F., et al. Mean diffusivity and fractional anisotropy as indicators of disease and genetic liability to schizophrenia. J Psychiatr Res 2011, 45:980-988.
84. Knöchel C., O'Dwyer L., Alves G., et al. Association between white matter fiber integrity and subclinical psychotic symptoms in schizophrenia patients and unaffected relatives. Schizophr Res 2012, 140:129-135.
85. Pérez-Iglesias R., Tordesillas-Gutiérrez D., Barker G.J., et al. White matter defects in first episode psychosis patients: A voxelwise analysis of diffusion tensor imaging. NeuroImage 2010, 49:199-204.
86. Filippi M., Canu E., Gasparotti R., et al. Patterns of brain structural changes in first-contact, antipsychotic drug-naive patients with schizophrenia. AJNR Am J Neuroradiol 2014, 35:30-37.
87. Wobrock T., Gruber O., Schneider-Axmann T., et al. Internal capsule size associated with outcome in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci 2009, 259:278-283.
88. Andreasen N.C., Nopoulos P., Magnotta V., Pierson R., Ziebell S., Ho B.C. Progressive brain change in schizophrenia: A prospective longitudinal study of first-episode schizophrenia. Biol Psychiatry 2011, 70:672-679.
89. Friedman J.I., Tang C., Carpenter D., et al. Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients. Am J Psychiatry 2008, 165:1024-1032.
90. Hoptman M.J., Nierenberg J., Bertisch H.C., et al. A DTI study of white matter microstructure in individuals at high genetic risk for schizophrenia. Schizophr Res 2008, 106:115-124.
91. Szeszko P.R., Robinson D.G., Ashtari M., et al. Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology 2008, 33:976-984.
92. Ehrlich S., Geisler D., Yendiki A., et al. Associations of White Matter Integrity and Cortical Thickness in Patients With Schizophrenia and Healthy Controls. Schizophr Bull 2014, 40:665-674.
93. Chiapponi C., Piras F., Piras F., Fagioli S., Caltagirone C., Spalletta G. Cortical grey matter and subcortical white matter brain microstructural changes in schizophrenia are localised and age independent: a case-control diffusion tensor imaging study. PLoS One 2013, 8:e75115.
94. Chiapponi C., Piras F., Fagioli S., Girardi P., Caltagirone C., Spalletta G. Hippocampus age-related microstructural changes in schizophrenia: a case-control mean diffusivity study. Schizophr Res 2014, 157:214-217.
95. Schobel S.A., Chaudhury N.H., Khan U.A., et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013, 78:81-93.
96. Moghaddam B., Javitt D. From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment. Neuropsychopharmacology 2012, 37:4-15.
97. O'Mara S. The subiculum: What it does, what it might do, and what neuroanatomy has yet to tell us. J Anat 2005, 207:271-282.
98. Mansur R.B., Zugman A., Asevedo E.D.M., Da Cunha G.R., Bressan R.A., Brietzke E. Cytokines in schizophrenia: Possible role of anti-inflammatory medications in clinical and preclinical stages. Psychiatry Clin Neurosci 2012, 66:247-260.
99. Monji A. The neuroinflammation hypothesis of psychiatric disorders. Seishin Shinkeigaku Zasshi 2012, 114:124-133.
100. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology 2009, 59:123-129.
101. Hope S., Melle I., Aukrust P., et al. Similar immune profile in bipolar disorder and schizophrenia: Selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 2009, 11:726-734.
102. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review. Biol Psychiatry 2008, 63:801-808.
103. Singh B., Bera N.K., Nayak C.R., Chaudhuri T.K. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009, 47:1-5.
104. Chang S.-H., Chiang S.-Y., Chiu C.-C., et al. Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia. Psychiatry Res 2010, 187:341-346.
105. Ellman L.M., Deicken R.F., Vinogradov S., et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res 2010, 121:46-54.
106. Brown A.S., Hooton J., Schaefer C.A., et al. Elevated Maternal Interleukin-8 Levels and Risk of Schizophrenia in Adult Offspring. Am J Psychiatry 2004, 161:889-895.
107. Watanabe Y., Someya T., Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: Evidence from human studies and animal models. Psychiatry Clin Neurosci 2010, 64:217-230.
108. Schwarz M.J., Müller N., Riedel M., Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001, 56:483-486.
109. Kauer-Sant'Anna M., Kapczinski F., Andreazza A.C., et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol 2009, 12:447-458.
110. Berk M., Conus P., Lucas N., et al. Setting the stage: From prodrome to treatment resistance in bipolar disorder. Bipolar Disord 2007, 9:671-678.
111. Berk M., Hallam K.T., McGorry P.D. The potential utility of a staging model as a course specifier: A bipolar disorder perspective. J Affect Disord 2007, 100:279-281.
112. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009, 9:957-966.
113. Craddock N., Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 2006, 14:660-668.
114. Carter C.J. Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: Implications for oligodendrocyte viability. Neurochem Int 2007, 50:461-490.
115. Mandelli L., Serretti A., Marino E., Pirovano A., Calati R., Colombo C. Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. Int J Neuropsychopharmacol 2007, 10:437-447.
116. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuro-Psychopharmacology Biol Psychiatry 2009, 33:1366-1371.
117. Strakowski S.M., DelBello M.P., Zimmerman M.E., et al. Ventricular and periventricular structural volumes in first- versus multiple-episode bipolar disorder. Am J Psychiatry 2002, 159:1841-1847.
118. O'Brien S.M., Scully P., Scott L.V., Dinan T.G. Cytokine profiles in bipolar affective disorder: Focus on acutely ill patients. J Affect Disord 2006, 90:263-267.
119. Ortiz-Domínguez A., Hernández M.E., Berlanga C., et al. Immune variations in bipolar disorder: Phasic differences. Bipolar Disord 2007, 9:596-602.
120. Brietzke E., Stertz L., Fernandes B.S., et al. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 2009, 116:214-217.
121. Kim Y.K., Jung H.G., Myint A.M., Kim H., Park S.H. Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 2007, 104:91-95.
122. Barbosa I.G., Huguet R.B., Mendonça V.A., et al. Increased plasma levels of soluble TNF receptor i in patients with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011, 261:139-143.
123. Hope S., Dieset I., Agartz I., et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011, 45:1608-1616.
124. Tsai S.Y., Chung K.H., Wu J.Y., Kuo C.J., Lee H.C., Huang S.H. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord 2012, 136:110-116.
125. Brietzke E., Kapczinski F. TNF-alpha as a molecular target in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1355-1361.
126. Bora E., Fornito A., Yücel M., Pantelis C. Voxelwise Meta-Analysis of Gray Matter Abnormalities in Bipolar Disorder. Biol Psychiatry 2010, 67:1097-1105.
127. Lin A., Reniers R.L.E.P., Wood S.J. Clinical staging in severe mental disorder: evidence from neurocognition and neuroimaging. Br J Psychiatry 2013, (Suppl. 54):s11-s17.
128. Javadapour A., Malhi G.S., Ivanovski B., Chen X., Wen W., Sachdev P. Increased anterior cingulate cortex volume in bipolar I disorder. Aust N Z J Psychiatry 2007, 41:910-916.
129. Lagopoulos J., Hermens D.F., Naismith S.L., Scott E.M., Hickie I.B. Frontal lobe changes occur early in the course of affective disorders in young people. BMC Psychiatry 2012, 12:4.
130. Yung A.R., Mcgorry P.D., Francey S.M., et al. PACE: a specialised service for young people at risk of psychotic disorders. Med J Aust 2007, 187(7 Suppl.):s43-s46.
131. Maier W., Zobel A., Wagner M. Schizophrenia and bipolar disorder: differences and overlaps. Curr Opin Psychiatry 2006, 19:165-170.
132. Lichtenstein P., Yip B.H., Björk C., et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009, 373:234-239.
133. Anis N.A., Berry S.C., Burton N.R., Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983, 79:565-575.
134. Gunduz-Bruce H. The acute effects of NMDA antagonism: From the rodent to the human brain. Brain Res Rev 2009, 60:279-286.
135. Snyder S.H. Dopamine receptor excess and mouse madness. Neuron 2006, 49:484-485.
136. Laursen T.M., Labouriau R., Licht R.W., Bertelsen A., Munk-Olsen T., Mortensen P.B. Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study. Arch Gen Psychiatry 2005, 62:841-848.
137. Maier W., Lichtermann D., Franke P., Heun R., Falkai P., Rietschel M. The dichotomy of schizophrenia and affective disorders in extended pedigrees. Schizophr Res 2002, 57:259-266.
138. Moskvina V., Craddock N., Holmans P., et al. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry 2009, 14:252-260.
139. Frank R.A.W., McRae A.F., Pocklington A.J., et al. Clustered coding variants in the glutamate receptor complexes of individuals with schizophrenia and bipolar disorder. PLoS One 2011, 6:e19011.
140. Craddock N., O'Donovan M.C., Owen M.J. Psychosis genetics: Modeling the relationship between schizophrenia, bipolar disorder and mixed (or "schizoaffective") psychoses. Schizophr Bull 2009, 35:482-490.
141. Chumakov I., Blumenfeld M., Guerassimenko O., et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Natl Acad Sci U S A 2002, 99:13675-13680.
142. Shifman S., Bronstein M., Sternfeld M., et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002, 71:1296-1302.
143. Straub R.E., Jiang Y., MacLean C.J., et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 2002, 71:337-348.
144. Berrettini W. Evidence for shared susceptibility in bipolar disorder and schizophrenia. Am J Med Genet C: Semin Med Genet 2003, 123C:59-64.
145. Kohn Y., Lerer B. Excitement and confusion on chromosome 6q: the challenges of neuropsychiatric genetics in microcosm. Mol Psychiatry 2005, 10:1062-1073.
146. Hattori E., Liu C., Badner J.A., et al. Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. Am J Hum Genet 2003, 72:1131-1140.
147. Schumacher J., Jamra R.A., Freudenberg J., et al. Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry 2004, 9:203-207.
148. Green E.K., Raybould R., Macgregor S., et al. Operation of the schizophrenia susceptibility gene, neuregulin 1, across traditional diagnostic boundaries to increase risk for bipolar disorder. Arch Gen Psychiatry 2005, 62:642-648.
149. Shifman S., Bronstein M., Sternfeld M., et al. COMT: a common susceptibility gene in bipolar disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004, 128B:61-64.
150. Schulze T.G., Ohlraun S., Czerski P.M., et al. Genotype-phenotype studies in bipolar disorder showing association between the DAOA/G30 locus and persecutory delusions: A first step toward a molecular genetic classification of psychiatric phenotypes. Am J Psychiatry 2005, 162:2101-2108.
151. Prata D.P., Breen G., Osborne S., Munro J., St Clair D., Collier D.A. An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. Psychiatr Genet 2009, 19:113-116.
152. Collier D.a., Li T. The genetics of schizophrenia: glutamate not dopamine?. Eur J Pharmacol 2003, 480:177-184.
153. Knickmeyer R.C., Wang J., Zhu H., et al. Common variants in psychiatric risk genes predict brain structure at birth. Cereb Cortex 2014, 24:1230-1246.
154. Cheung C., Yu K., Fung G., et al. Autistic disorders and schizophrenia: Related or remote? An anatomical likelihood estimation. PLoS One 2010, 5:e12233.
155. Yu K., Cheung C., Leung M., Li Q., Chua S., McAlonan G. Are Bipolar Disorder and Schizophrenia Neuroanatomically Distinct? An Anatomical Likelihood Meta-analysis. Front Hum Neurosci 2010, 4:189.
156. Scharinger C., Rabl U., Sitte H.H., Pezawas L. Imaging genetics of mood disorders. NeuroImage 2010, 53:810-821.
157. Johnstone M., Thomson P.A., Hall J., McIntosh A.M., Lawrie S.M., Porteous D.J. DISC1 in schizophrenia: Genetic mouse models and human genomic imaging. Schizophr Bull 2011, 37:14-20.
158. Gilmore J.H., Lin W., Prastawa M.W., et al. Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. J Neurosci 2007, 27:1255-1260.
159. Knickmeyer R.C., Gouttard S., Kang C., et al. A structural MRI study of human brain development from birth to 2years. J Neurosci 2008, 28:12176-12182.
160. Rapoport J.L., Addington A.M., Frangou S., Psych M.R.C. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005, 10:434-449.
161. Fatemi S.H., Folsom T.D. The neurodevelopmental hypothesis of Schizophrenia, revisited. Schizophr Bull 2009, 35:528-548.
162. Gilmore J.H., Kang C., Evans D.D., et al. Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. Am J Psychiatry 2010, 167:1083-1091.
163. Haukvik U.K., Westlye L.T., Mørch-Johnsen L., et al. In Vivo Hippocampal Subfield Volumes in Schizophrenia and Bipolar Disorder. Biol Psychiatry 2014, 77:581-588.
164. O'Mara S.M., Sanchez-Vives M.V., Brotons-Mas J.R., O'Hare E. Roles for the subiculum in spatial information processing, memory, motivation and the temporal control of behaviour. Prog Neuro-Psychopharmacology Biol Psychiatry 2009, 33:782-790.
165. Zanelli J., Reichenberg A., Morgan K., et al. Specific and generalized neuropsychological deficits: A comparison of patients with various first-episode psychosis presentations. Am J Psychiatry 2010, 167:78-85.
166. Simonsen C., Sundet K., Vaskinn A., et al. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group. Schizophr Bull 2011, 37:73-83.
167. Ellison-Wright I., Bullmore E. Anatomy of bipolar disorder and schizophrenia: A meta-analysis. Schizophr Res 2010, 117:1-12.
168. Matsuo K., Walss-Bass C., Nery F.G., et al. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder. Neuropsychopharmacology 2009, 34:1904-1913.
169. Cheniaux E., Landeira-Fernandez J., Lessa Telles L., et al. Does schizoaffective disorder really exist? A systematic review of the studies that compared schizoaffective disorder with schizophrenia or mood disorders. J Affect Disord 2008, 106:209-217.
170. Van Snellenberg J.X., de Candia T. Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder. Arch Gen Psychiatry 2009, 66:748-755.
171. Kotov R., Leong S.H., Mojtabai R., et al. Boundaries of schizoaffective disorder: revisiting Kraepelin. JAMA Psychiatry 2013, 70:1276-1286.
172. Atkinson A.J., Colburn W.A., DeGruttola V.G., et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
173. Malhi G.S. ICD future. Aust N Z J Psychiatry 2014, 48:107-109.
174. Maccarrone G., Ditzen C., Yassouridis A., et al. Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters. J Psychiatr Res 2013, 47:1572-1580.
175. Frey B.N., Andreazza A.C., Houenou J., et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry 2013, 47:321-332.
176. Gootjes L., Teipel S.J., Zebuhr Y., et al. Regional distribution of white matter hyperintensities in vascular dementia, Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord 2004, 18:180-188.
177. Duffy A., Lewitzka U., Doucette S., Andreazza A., Grof P. Biological indicators of illness risk in offspring of bipolar parents: Targeting the hypothalamic-pituitary-adrenal axis and immune system. Early Interv Psychiatry 2012, 6:128-137.
178. Van der Werf-Eldering M.J., Riemersma-van der Lek R.F., Burger H., Holthausen E.A.E., Aleman A., Nolen W.A. Can variation in hypothalamic-pituitary-adrenal (HPA)-axis activity explain the relationship between depression and cognition in bipolar patients?. PLoS One 2012, 7:e37119.
179. Grande I., Fries G.R., Kunz M., Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig 2010, 7:243-250.
180. Fernandes B.S., Gama C.S., Maria Ceresér K., et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis. J Psychiatr Res 2011, 45:995-1004.
181. Schwarz E., Guest P.C., Rahmoune H., et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2012, 17:494-502.
182. Gur R.E., Kohler C.G., Ragland J.D., et al. Flat affect in schizophrenia: Relation to emotion processing and neurocognitive measures. Schizophr Bull 2006, 32:279-287.
183. Evensen J., Røssberg J.I., Barder H., et al. Flat affect and social functioning: a 10year follow-up study of first episode psychosis patients. Schizophr Res 2012, 139:99-104.
184. Takayanagi M., Wentz J., Takayanagi Y., et al. Reduced anterior cingulate gray matter volume and thickness in subjects with deficit schizophrenia. Schizophr Res 2013, 150:484-490.
185. Popovic D., Reinares M., Scott J., et al. Polarity index of psychological interventions in maintenance treatment of bipolar disorder. Psychother Psychosom 2013, 82:292-298.
186. Carvalho A.F., McIntyre R.S., Dimelis D., et al. Predominant polarity as a course specifier for bipolar disorder: a systematic review. J Affect Disord 2014, 163:56-64.
187. Widiger T.A., Samuel D.B. Diagnostic Categories or Dimensions? A Question for the Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition. J Abnorm Psychol 2005, 114:494-504.